Search results for "AGENT"

showing 10 items of 8904 documents

Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract.

2004

Limited studies have been carried out on the biotransformation of carboxyl nonsteroidal anti-inflammatory drugs (NSAIDs) in the liver. However, the role of the intestine in NSAID metabolism has not been investigated. In this report, the contribution of UDP-glucuronosyltransferases (UGTs) in the human gastrointestinal (GI) tract from five donors to the glucuronidation of the NSAIDs, RS-ketoprofen, S-naproxen, RS- and S-etodolac, was investigated. UGT activity and, for some donors, mRNA levels were evaluated. All NSAIDs were glucuronidated throughout the GI tract; however, glucuronidation was low in stomach and duodenum as compared to the remainder of the intestine. RT-PCR analysis demonstrat…

medicine.medical_specialtyBiophysicsGlucuronidationAdministration OralPharmacologydigestive systemBiochemistryGene Expression Regulation EnzymologicFirst pass effectGlucuronidesNaproxenInternal medicineMicrosomesmedicineHumansRNA MessengerGlucuronosyltransferaseMolecular BiologyChromatography High Pressure LiquidGastrointestinal tractChemistryReverse Transcriptase Polymerase Chain ReactionStomachHuman gastrointestinal tractAnti-Inflammatory Agents Non-SteroidalUGT2B7Gastrointestinal Tractmedicine.anatomical_structureEndocrinologyKetoprofenDuodenumMicrosomeEtodolacBiochimica et biophysica acta
researchProduct

Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis.

2018

Background: Treatment-emergent mania (TEM) represents a common phenomenon inconsistently reported across primary studies, warranting further assessment. Methods: A systematic review and meta-analysis following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines were conducted. Major electronic databases were searched from inception to May 2017 to assess the incidence and prevalence rates and clinical features associated with manic switch among bipolar depressed patients receiving antidepressants, using meta-regression and subgroup analysis. Results: Overall, 10 098 depressed patients wit…

medicine.medical_specialtyBipolar DisorderSubgroup analysismeta-analysinot knownlaw.invention03 medical and health sciences0302 clinical medicineantidepressant; bipolar disorder; incidence; meta-analysis; switch; systematic reviewsystematic reviewRandomized controlled triallawInternal medicinemedicinePrevalenceHumansCumulative incidenceBipolar disorderBiological Psychiatryantidepressantbusiness.industryDepressionIncidence (epidemiology)Incidencemedicine.diseaseswitchConfidence intervalAntidepressive Agents030227 psychiatrymeta-analysisPsychiatry and Mental healthMeta-analysismedicine.symptombusinessMania030217 neurology & neurosurgeryBipolar disorders
researchProduct

Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysi…

2010

In recent years, combinations of pharmacological treatments have become common for the treatment of bipolar disorder type I (BP I); however, this practice is usually not evidence-based and rarely considers monotherapy drug regimen (MDR) as an option in the treatment of acute phases of BP I. Therefore, we evaluated comparative data of commonly prescribed MDRs for both manic and depressive phases of BP I. Medline, PsycINFO, EMBASE, the Cochrane Library, the ClinicalStudyResults.org and other data sources were searched from 1949 to March 2009 for placebo and active controlled randomized clinical trials (RCTs). Risk ratios (RRs) for response, remission, and discontinuation rates due to adverse …

medicine.medical_specialtyBipolar I disorderBipolar DisorderDatabases FactualPharmacologyLithiumArticlelaw.inventionTreatment of bipolar disorderRandomized controlled triallawInternal medicinemental disordersmedicineAnimalsHumansManic-depressive illnessPharmacology (medical)Bipolar disorderAntipsychotic drugsRandomized Controlled Trials as TopicPharmacologyTrastorn bipolarbusiness.industrymedicine.diseaseLitiAntidepressive AgentsDiscontinuationPsychiatry and Mental healthAcute DiseaseNumber needed to treatAnticonvulsiusQuetiapineDrug EvaluationAntipsicòticsAnticonvulsantsmedicine.symptombusinessManiamedicine.drug
researchProduct

Characteristics of bipolar disorder patients given antidepressants

2012

Evidence concerning efficacy of antidepressants in bipolar disorder remains inconsistent and inconclusive. As the appropriate clinical use for such patients remains unclear, we characterized outpatients with bipolar disorders who were or were not treated with antidepressants. Clinical data were collected systematically from consecutive outpatients in 11 participating Argentine mood-disorder clinics in 2007–2008. Diagnoses met DSM-IV criteria, supported by structured interviews based on the MINI-500. Of 338 outpatients diagnosed with bipolar I (45.0%), II (29.3%), or not-otherwise-specified (NOS) (25.7%) disorder, 128 (37.9%) received antidepressants. Subjects given antidepressants or not di…

medicine.medical_specialtyBipolar I disorderbusiness.industrymedicine.diseaseAntimanic AgentsPsychiatry and Mental healthNeurologyInternal medicineMedicineOutpatient clinicAntidepressantPharmacology (medical)Neurology (clinical)Bipolar disorderbusinessPsychiatryDepression (differential diagnoses)Human Psychopharmacology: Clinical and Experimental
researchProduct

Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines

2004

Abstract In this study, we tested and compared the endocrine disruption activities of compounds in materials used to package foods (bisphenol A, bisphenol F, and bisphenol A diglycidylether BADGE) with natural molecules (genistein, apigenin, kaempferol, and tangeretin) in the human breast cancer cell lines MCF-7 (ER + ) and MDA-MB453 (AR + ; GR + ). Octylphenol was also chosen as a xenoestrogen reference. Two compounds had no estrogenic activity: BADGE and tangeretin. Genistein was the most active compound in the E-Screen assay with MCF-7, followed by octylphenol, bisphenol F, bisphenol A and apigenin, with kaempferol the least potent. All estrogenic compounds competed with 17β-estradiol fo…

medicine.medical_specialtyBisphenol A[SDV]Life Sciences [q-bio]medicine.medical_treatmentGenisteinAntineoplastic AgentsBreast NeoplasmsEndocrine SystemToxicologySteroid03 medical and health scienceschemistry.chemical_compoundTangeretin0302 clinical medicinePhenolsInternal medicineTumor Cells CulturedmedicineAnticarcinogenic AgentsHumansEstrogens Non-SteroidalApigeninBenzhydryl CompoundsKaempferolsComputingMilieux_MISCELLANEOUS030304 developmental biologyFlavonoids0303 health sciencesDose-Response Relationship DrugFood PackagingGeneral MedicineFlavonesGenistein3. Good health[SDV] Life Sciences [q-bio]XenoestrogenEndocrinologyReceptors EstrogenchemistryMCF-7Receptors Androgen030220 oncology & carcinogenesisApigeninCarcinogensEpoxy CompoundsFemaleKaempferolhormones hormone substitutes and hormone antagonistsFood Science
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats

2017

Background The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats. Material and Methods 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariectomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and OVX / ZOL group underwent ovariectomy. After 12 weeks, rats from OVX / ZOL were injected with 0.04 mg/kg ZOL intravenously once a week for 6 weeks. The rats from CTRL and OVX groups were injected with 0.9% NaCl. Implants were placed in the left tibia. Afte…

medicine.medical_specialtyBone densityOvariectomyDentistryZoledronic AcidOsseointegration03 medical and health sciences0302 clinical medicineAbsorptiometry PhotonBone DensityOsseointegrationInternal medicineMedicineAnalysis softwareAnimalsTibiaRats WistarGeneral DentistryBone mineralDental ImplantsBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchSham surgeryImidazoles030206 dentistry:CIENCIAS MÉDICAS [UNESCO]RatsZoledronic acidEndocrinologyOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASOvariectomized ratSurgeryFemaleOral Surgerybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis

2007

Recently, jawbone osteonecrosis has been largely reported as a potential adverse effect of bisphosphonate (BP) administration. Because of the peculiar pharmacokinetic and pharmacodynamic features of the BF (mainly for i.v. administration), their efficacy and large use, some major issues have to be taken into account extendedly both by oncologists and by dentists: 1) therapeutic dental protocol for patients with diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ); 2) dental strategies for patients in former or current i.v. BF treatment and in absence of BRONJ signs; 3) strategies for patients before i.v. BF treatment. Clinical features and guidelines for the management of th…

medicine.medical_specialtyBone diseasemedicine.medical_treatmentDentistryBone NeoplasmsJaw neoplasmPatient Education as TopicmedicineHumansDental Restoration PermanentIntensive care medicineAdverse effectbisphosphonates metastatic bone diseaseBone Density Conservation AgentsDiphosphonatesbusiness.industrySurrogate endpointAdvanced stageOsteonecrosisHematologyBisphosphonatemedicine.diseaseJaw NeoplasmsOncologybusinessOsteonecrosis of the jawAnnals of Oncology
researchProduct

Effect of uric acid in animal models of ischemic stroke: A systematic review and meta-analysis

2020

Addition of uric acid (UA) to thrombolytic therapy, although safe, showed limited efficacy in improving patients’ stroke outcome, despite alleged neuroprotective effects of UA in preclinical research. This systematic review assessed the effects of UA on brain structural and functional outcomes in animal models of ischemic stroke. We searched Medline, Embase and Web of Science to identify 16 and 14 eligible rodent studies for qualitative and quantitative synthesis, respectively. Range of evidence met 10 of a possible 13 STAIR criteria. Median (Q1, Q3) quality score was 7.5 (6, 10) on the CAMARADES 15-item checklist. For each outcome, we used standardised mean difference (SMD) as effect size…

medicine.medical_specialtyBrain damageNeuroprotectionMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAnimal modelFibrinolytic AgentsInternal medicineStroke outcomeIschaemic strokeAnimalsHumansMedicineThrombolytic TherapyReview ArticlesIschemic Stroke030304 developmental biology0303 health sciencesbusiness.industryRecovery of FunctionRatsUric AcidNeurologychemistryMeta-analysisIschemic strokeCardiologyUric acidNeurology (clinical)Nervous System Diseasesmedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct